Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer

Video

Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.

Giuseppe Curigliano, MD, PhD, discusses data from the following study:

  • Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). (Curigliano, Journal of Clinical Oncology, Abstract 1043)
    • The objective of this study is to report results in patients with pretreated HER2+ metastatic breast cancer with and without brain metastases treated with tucatinib vs placebo added to trastuzumab and capecitabine.
    • Tucatinib is an oral tyrosine kinase inhibitor (TKI) highly specific for HER2.
    • 612 patients were randomized 2:1 to receive tucatinib 300 mg twice a day or placebo, each in combination with trastuzumab and capecitabine.
    • Efficacy outcomes were assessed in the population for each agent:
      • Progression-free survival (PFS) assessed by blinded independent central review based on RECIST 1.1.
      • Overall survival (OS) and safety and tolerability of the regimens assessed.
    • Conclusions:
      • Overall survival benefit with tucatinib was maintained with an additional 15.6 months of follow-up (29.6 months total), with a 5.5-month improvement in median OS in the total population.
        • Overall survival benefit also maintained across all prespecified subgroups.
      • Improvement in overall survival observed in patients with and without visceral metastases was clinically meaningful.
      • Progression-free survival benefit based on investigator assessment was consistent with the primary analysis.
      • Tucatinib in combination with trastuzumab and capecitabine was well tolerated with a low rate of discontinuation due to adverse events.
        • Discontinuations due to adverse events were infrequent in both arms.
        • Rates of liver lab abnormalities and diarrhea remained stable with longer follow-up.
        • Safety profile was consistent with the primary analysis.
Related Videos
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"